Shockwave Medical Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Doug Godshall

İcra Kurulu Başkanı

US$9.5m

Toplam tazminat

CEO maaş yüzdesi	7.6%
CEO görev süresi	7yrs
CEO sahipliği	0.3%
Yönetim ortalama görev süresi	2.3yrs
Yönetim Kurulu ortalama görev süresi	5.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Doug Godshall'un ücretlendirmesi Shockwave Medical'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2024	n/a	n/a	US$163m
Dec 31 2023	US$9m	US$716k	US$147m
Sep 30 2023	n/a	n/a	US$244m
Jun 30 2023	n/a	n/a	US$244m
Mar 31 2023	n/a	n/a	US$241m
Dec 31 2022	US$8m	US$644k	US$216m
Sep 30 2022	n/a	n/a	US$88m
Jun 30 2022	n/a	n/a	US$55m
Mar 31 2022	n/a	n/a	US$29m
Dec 31 2021	US$7m	US$575k	-US$9m
Sep 30 2021	n/a	n/a	-US$38m
Jun 30 2021	n/a	n/a	-US$53m
Mar 31 2021	n/a	n/a	-US$71m
Dec 31 2020	US$5m	US$546k	-US$66m
Sep 30 2020	n/a	n/a	-US$65m
Jun 30 2020	n/a	n/a	-US$65m
Mar 31 2020	n/a	n/a	-US$57m
Dec 31 2019	US$2m	US$477k	-US$51m
Sep 30 2019	n/a	n/a	-US$48m
Jun 30 2019	n/a	n/a	-US$45m
Mar 31 2019	n/a	n/a	-US$44m
Dec 31 2018	US$511k	US$376k	-US$41m

Tazminat ve Piyasa: Doug 'nin toplam tazminatı ($USD 9.48M ), BR pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.78M ).

Tazminat ve Kazançlar: Doug 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Doug Godshall (58 yo)

7yrs

Görev süresi

US$9,478,729

Tazminat

Mr. Douglas E. Godshall, also known as Doug, M.B.A., is Director of Saluda Medical, Inc. He serves as Chair of the Board of Galvanize Therapeutics, Inc. since September 2022. He has been the Chief Executiv...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Douglas Godshall	President	7yrs	US$9.48m	0.29% R$ 190.2m
Isaac Zacharias	President & Chief Commercial Officer	1.9yrs	US$3.23m	0.15% R$ 98.2m
Daniel Hawkins	Founder and Senior Advisor	15.3yrs	Veri yok	Veri yok
John Adams	Co-Founder and Technical Advisor	15.3yrs	Veri yok	Veri yok
Renee Gaeta	Chief Financial Officer	less than a year	Veri yok	0.053% R$ 34.7m
Luis Morales	Senior Vice President of Global Operations	less than a year	Veri yok	Veri yok
Trinh Phung	Chief Accounting Officer	2.3yrs	Veri yok	0.13% R$ 87.9m
Debbie Kaster	Vice President of Investor Relations	less than a year	Veri yok	Veri yok
Hajime Tada	General Counsel & Secretary	4.9yrs	Veri yok	Veri yok
Robert Fletcher	Senior Vice President of Marketing & Market Access	7.8yrs	Veri yok	Veri yok
Dave Cox	Vice President of Sales	less than a year	Veri yok	Veri yok
Cathy Harnett	Senior Director of Human Resources	2.3yrs	Veri yok	Veri yok

2.3yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: S2WA34 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Douglas Godshall	President	7yrs	US$9.48m	0.29% R$ 190.2m
Antoine Papiernik	Independent Director	10.8yrs	US$277.06k	Veri yok
Frederic Moll	Independent Director	13yrs	US$273.62k	0.76% R$ 498.4m
Charles Larkin	Independent Chairman of the Board	5.3yrs	US$333.62k	0.012% R$ 7.9m
Laura Francis	Independent Director	5.3yrs	US$297.37k	0.011% R$ 7.1m
Sara Toyloy	Independent Director	3.2yrs	US$278.62k	0.0052% R$ 3.4m
Maria Sainz	Independent Director	3.8yrs	US$289.87k	0.0096% R$ 6.3m
Kevin Ballinger	Independent Director	less than a year	US$508.05k	Veri yok
F. Watkins	Independent Director	10.9yrs	US$278.62k	0.010% R$ 6.6m

5.3yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: S2WA34 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.3 yıldır).

Shockwave Medical Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Shockwave Medical, Inc. Announces Termination of Employment of Renee Gaeta as Chief Financial Officer

Shockwave Medical, Inc., Annual General Meeting, May 29, 2024

Shockwave Medical, Inc. Appoints Renee Gaeta as Chief Financial Officer, Effective February 5, 2024

Shockwave Medical, Inc. Appoints Nick West as Associate Chief Medical Officer

Daniel K. Puckett Notifies Shockwave Medical, Inc. of His Intention to Retire as Chief Financial Officer

Daniel K. Puckett Notifies Shockwave Medical, Inc. of His Intention to Retire as Chief Financial Officer

Recent updates

Shockwave Medical, Inc. Announces U.S. Launch of the Shockwave E8 Peripheral Ivl Catheter

Shockwave Medical Files Form 15

Shockwave's Common Stock Ceases Trading on NASDAQ

Shockwave Medical, Inc. Announces Termination of Employment of Renee Gaeta as Chief Financial Officer

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Shockwave Medical, Inc. (NasdaqGS:SWAV) from a group of sellers.

Shockwave Medical Withdraws Earnings Guidance for the Full Year 2024

Shockwave Medical, Inc., Annual General Meeting, May 29, 2024

Shockwave Medical, Inc. Announces Investigators Presented Six-Month Data from the Full Population of the Reducer-I Study

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Shockwave Medical, Inc. (NasdaqGS:SWAV) for $13 billion.

Johnson & Johnson Reportedly Considers Deal for Shockwave Medical

Shockwave Medical, Inc. Provides Earnings Guidance for 2024

Shockwave Medical, Inc. Appoints Renee Gaeta as Chief Financial Officer, Effective February 5, 2024

Shockwave Medical, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Shockwave Medical, Inc. Announces New Data Demonstrating One-Year Outcomes with Coronary Lithotripsy

Shockwave Medical, Inc. Provides Revenue Guidance for the Full Year 2023

Shockwave Medical, Inc. Introduces Enhanced Coronary IVL Catheter in the United States

Shockwave Medical, Inc. Announces New Shockwave Coronary IVL Publications Confirm Safety and Efficacy Across Multiple Calcium Morphologies

Shockwave Medical, Inc. Appoints Nick West as Associate Chief Medical Officer

Daniel K. Puckett Notifies Shockwave Medical, Inc. of His Intention to Retire as Chief Financial Officer

Daniel K. Puckett Notifies Shockwave Medical, Inc. of His Intention to Retire as Chief Financial Officer

Shockwave Medical, Inc. Revises Revenue Guidance for the Full Year 2023

Shockwave Medical, Inc.(NasdaqGS:SWAV) dropped from Russell 2000 Dynamic Index

Shockwave Medical, Inc. Appoints Kevin Ballinger to Board of Directors and Will Serve on Shockwave’s Nominating and ESG Committee and the Compensation Committee of the Board

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical, Inc. Revises Revenue Guidance for the Year 2023

Shockwave Medical, Inc. Provides Earnings Guidance for the Full Year 2023

ShockWave Medical, Inc. (NasdaqGS:SWAV) entered into a definitive agreement to acquire Neovasc Inc. (TSX:NVCN) from Strul Medical Group LLC and others for $75.04 million.

ShockWave Medical, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2022 and Fiscal Year 2023

ShockWave Medical, Inc. to Report Q4, 2022 Results on Feb 16, 2023

ShockWave Medical, Inc. Revises Revenue Guidance for the Year 2022

ShockWave Medical, Inc. Confirms Consistent Outcomes for IVL in the larger Prospective “Real World” Study of Patients with Heavily Calcified Peripheral Arterial Disease

ShockWave Medical, Inc. Revises Revenue Guidance for the Full Year 2022

Shockwave Medical, Inc. and Genesis MedTech Group Successfully Obtains Approval from China’S National Medical Products Administration to Market and Sell the Shockwave IVL System with the Shockwave C2 Coronary IVL Catheters and the Shockwave M5 and S4 Peripheral IVL Catheters in China

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş